1318 - Frequency and spectrum of EGFR mutations in Moroccan lung adenocarcinoma patients

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Biomarkers
Non-Small-Cell Lung Cancer, Metastatic
Presenter Ibrahim Elghissassi
Authors I. Elghissassi1, H. Inrhaoun2, A. Boukir2, Y. Bensouda2, H. Mrabti3, H. Errihani4
  • 1Medical Oncology, Institut National d'Oncologie Sidi Mohamed Ben Abdellah, 10000 - Rabat/MA
  • 3Medical Oncology, Institut National d'OncologieSidi Mohamed Ben Abdellah, MA-10000 - Rabat/MA
  • 4Institut National d'OncologieSidi Mohamed Ben Abdellah, MA-10000 - Rabat/MA



EGFR mutations reported in lung cancer are potential therapeutic targets leading to improved response with tyrosine kinase inhibitors (TKI). The frequency of EGFR mutations is ethnicity-dependent with a higher proportion in Asian populations (30%) than in Caucasians (10-15%). Furthermore, exon 19 mutation is associated with better response to EGFR-TKI compared to exon 21 mutation. The aim of this study was to report the frequency and spectrum of EGFR mutations in unselected group of Moroccan lung adenocarcinoma patients.


We summarized the result of the EGFR mutation analysis in exons 18-21 for 83 patients performed from November 2010 to march 2012 in three laboratories in Rabat. Mutation detection techniques were PCR amplification and sequencing. Only Moroccan lung adenocarcinoma patients were included.


The overall frequency of the EGFR mutation was 22%. It was more frequent in female patients (58%) than in male ones (5%). Mutations were mainly detected in the exon 19 (67%) followed by exon 21 (17%) and exon 20 (11%), while that in the exon 18 was rare (5%).


Some one fifth of Moroccan lung adenocarcinoma tumors harbor EGFR mutations. This mutation frequency is higher than that found in Caucasians but lower than in Asian population. The high rate of exon 19 mutation in Moroccan population may result in a higher frequency of response to TKI


All authors have declared no conflicts of interest.